



MARKET ANNOUNCEMENT

Oxycom - New US patent for Uscom

Thursday, 7 August 2008: Uscom (ASX Code: UCM) today received its US patent no 7338447, the method for combining blood flow measurement (USCOM) with oximetry to provide a non-invasive measure of the amount of oxygen being delivered to the cells of the body. The granting of the US patent is recognition of the novelty and inventiveness of the method by the US Patent Office and provides commercial protection for the Oxycom device, a new product from Uscom Ltd.

Oxygen delivery via the circulation is fundamental to the health of the body and is disturbed in many common diseases. This is the first device which allows for accurate and non-invasive measurement of oxygen delivery and promises to be useful in many clinical applications including Paediatrics, Intensive Care and Emergency Medicine, and Anaesthesia.

The patent author and Chairman of Uscom Ltd, Rob Phillips said *“Oxygen delivery is a critical measure of the effectiveness of the circulation, and reflects the severity of cardiovascular disease. The new Oxycom product, currently in testing, provides this information non-invasively and beat to beat; a first in the world of physiology and medicine.”*

Uscom CEO, Paul Butler, said *“Intellectual property (IP) represents a significant component of the value of Uscom, and patents provide commercial protection for future product developments. This patent and the product it protects provide a great opportunity for Uscom to strengthen its position in the cardiovascular device marketplace and increase the value of the Company.”*

Uscom continues to develop IP as part of the process of developing innovative solutions to important clinical problems and has over 30 patents and intellectual protection applications in various stages of recognition around the world. This IP forms the commercial protection for a pipeline of new devices planned for development by the Company and is significant part of a shareholder value.

About Uscom

Uscom Limited (UCM) is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a non-invasive device for the safe and accurate measurement of cardiac output, as an alternative to the current invasive methods. The device provides real-time beat-to-beat information across multiple parameters of cardiac function and provides advanced trending capabilities, allowing clinicians to accurately quantify the effect of treatment. The device is ideally suited to Paediatrics, Intensive Care and Emergency Medicine, and Anaesthesia where it is critical to monitor changes in cardiac output as fluids and drugs are administered.

Uscom holds a number of national and international patents and patent applications predominantly related to cardiovascular assessment.

The Company has secured regulatory approval for sale of the USCOM 1A Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts

Paul Butler
Chief Executive Officer
Office: 02 9247 4144
paul.butler@uscom.com.au

Rob Phillips
Executive Chairman
Office: 02 9247 4144
rob@uscom.com.au